Global Acute Hepatic Porphyria Treatment Market, By Types (Acute Intermittent Porphyria (AIP), Hereditary Coproporphyria (HCP) and Others), Treatment (Medications, Caloric Deprivation, Dehydration and Others), Route of Administration (Oral, Parenteral and Others), End-Users (Hospitals, Homecare, Specialty Clinics, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy) – Industry Trends and Forecast to 2030.
Acute Hepatic Porphyria Treatment Market Analysis and Size
As per the NCBI, the global occurrence of acute hepatic porphyria is anticipated to vary from one in 500 to one in 50,000 individuals. Acute hepatic porphyria (AHP) is one of the types of hepatic porphyria. The incidence of clinical acute hepatic porphyria is stated to be around 5 to 10 per 100,000 individuals. It is witnessed that the persistent increase in research grants and R&D expenditures from government and other pharma companies to boost the development of rare disease drugs that would change the scenario of porphyrias treatment.
Data Bridge Market Research analyses a growth rate in acute hepatic porphyria treatment market in the forecast period 2023-2030. The expected CAGR of acute hepatic porphyria treatment market is tend to be around 5% in the mentioned forecast period. The market was valued at USD 3.72 million in 2022, and it would grow upto USD 5.5 million by 2030. In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team also includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Acute Hepatic Porphyria Treatment Market Scope and Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2023-2030
|
|
Base Year
|
2022
|
|
Historic Years
|
2021 (Customizable to 2015 - 2020)
|
|
Quantitative Units
|
Revenue in USD Million, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
Types (Acute Intermittent Porphyria (AIP), Hereditary Coproporphyria (HCP) and Others), Treatment (Medications, Caloric Deprivation, Dehydration and Others), Route of Administration (Oral, Parenteral and Others), End-Users (Hospitals, Homecare, Specialty Clinics, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy)
|
|
Countries Covered
|
U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America
|
|
Market Players Covered
|
Teva Pharmaceutical Industries Ltd (Israel), Apotex Inc (Canada), Pfizer Inc (U.S.), H. Lundbeck A/S (Denmark), Lilly (U.S.), F. Hoffmann-La Roche Ltd. (Switzerland), Mylan N.V. (U.S.), Siemens Healthcare GmbH (Germany.), ACON Laboratories, Inc. (U.S.), Danaher. (U.S.), ARKRAY, Inc (Japan), Abbott (U.S.), Alnylam Pharmaceuticals, Inc(U.S.), Boston Scientific Corporation (U.S.), Bio-Rad Laboratories, Inc. (U.S.), Recordati Rare Diseases Inc (Italy)
|
|
Market Opportunities
|
|
Market Definition
Acute hepatic porphyria is a group of inherited diseases that are genetically different in nature; thoough, they are caused because of overproduction of heme precursors. The clinical symptoms include chest pain, vomiting, muscles pain, nausea, weakness and others. Porphyrias treatment may include evading the triggers, consumption of medicines to relieve symptoms, receiving heme through a vein, or sometimes having blood drawn to decrease iron in the body. Currently, there is no proper cure for this condition
Acute Hepatic Porphyria Treatment Market Dynamics
Drivers
- Growing Demands of Diagnostic Tests
There are numerous diagnostic tests that are boosting the demand of the market. Genetic testing is the primary standard test for diagnosing this condition. A genetic test can check if the person has one gene mutation that can cause AHP. It can also tell what type of AHP the patient have and how serious the enzyme deficiency is. A genetic test uses a sample of your blood or saliva. Thus, it increases the demand of the treatment drugs.
- Growing Incidences Of Acute Hepatic Porphyria
As per the records of NCBI, the global incidence of acute hepatic porphyria is estimated to range from one in 500 to one in 50,000 individuals. In most of the regions, acute intermittent porphyria (AIP) is the most common, and ALA dehydratase-deficiency porphyria (ALAD) is the least common. The incidence of clinical AIP is witnessed to be around 5 to 10 per 100,000 individuals, and the incidence of genetic mutations of AIP is around one in 1675 individuals. This high rate of incidence is likely to drive the demand for the market.
Opportunities
- Growing Demand of Diverse Treatment Methods
There are several treatment methods that are aiding in boosting the growth of the market. Panhematin is the only commercially available heme therapy in the U.S. for this condition. People suffering from severe porphyric attacks are treated with heme given by vein. If porphyrias treatment is postponed, then recovery takes longer and nerve damage may be long-lasting. Additionally, a high carbohydrate diet and intravenous glucose therapy for mild attacks are generally advised for porphyrias treatment. Liver transplantation is suggested for acute intermittent porphyria.
Restraints/Challenges
- Discontinuation of Drug Trials
The drug development for the disease has faced foremost obstacles as numerous therapies have failed to reveal efficacy or were associated with major toxicity. Therefore, this hampers the growth of the market.
This acute hepatic porphyria treatment market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the acute hepatic porphyria treatment market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
Global Acute Hepatic Porphyria Treatment Market Scope
The acute hepatic porphyria treatment market is segmented on the basis of treatment, type, route of administration, distribution channel and end-user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Types
- Acute Intermittent Porphyria (AIP)
- Hereditary Coproporphyria (HCP)
- Others
Treatment
- Medications
- Caloric Deprivation
- Dehydration
- Others
Route of Administration
- Oral
- Parenteral
- Others
End User
- Hospitals
- Homecare
- Specialty Clinics
- Others
Distribution Channel
- Hospital Pharmacy
- Online Pharmacy
- Retail Pharmacy
Acute Hepatic Porphyria Treatment Market Regional Analysis/Insights
The acute hepatic porphyria treatment market is analyzed and market size insights and trends are provided by treatment, type, route of administration, distribution channel and end-user as referenced above.
The major countries covered in the acute hepatic porphyria treatment market report are the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
Asia-Pacific will be expecting positive growth for acute hepatic porphyria treatment market throughout the forecasted period due to growing awareness among the population and increase in patient population.
North America dominates the market due to well-defined reimbursement policies from several public and private health insurance firms that help provide patients easy access of diagnosis and wide R&D activities. In the U.S., about 5,000 people experience one or more of acute hepatic porphyria attacks yearly.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Competitive Landscape and Global Acute Hepatic Porphyria Treatment Market Share Analysis
The acute hepatic porphyria treatment market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to acute hepatic porphyria treatment market.
Key players operating in the acute hepatic porphyria treatment market include:
- Teva Pharmaceutical Industries Ltd (Israel)
- Apotex Inc (Canada)
- Pfizer Inc (U.S.)
- H. Lundbeck A/S (Denmark)
- Lilly (U.S.)
- F. Hoffmann-La Roche Ltd. (Switzerland)
- Mylan N.V. (U.S.)
- Siemens Healthcare GmbH (Germany)
- ACON Laboratories, Inc. (U.S.)
- Danaher. (U.S.)
- ARKRAY, Inc (Japan)
- Abbott (U.S.)
- Alnylam Pharmaceuticals, Inc (U.S.)
- Boston Scientific Corporation (U.S.)
- Bio-Rad Laboratories, Inc. (U.S.)
- Recordati Rare Diseases Inc (Italy)
SKU-